Several key players are shaping the global pruritus therapeutics market. Companies such as Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical ...

Abstract #5038: Volixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: An Adaptive, Randomized, Placebo-controlled Phase 2b Trial (VANTAGE): Interim Results **Late-breaker poster ...

“Winter itch, also known as pruritus hiemalis, is a common type of dermatitis (skin irritation or inflammation) caused by ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello everyone, and welcome to the Mirum Pharmaceuticals’ Third ...

Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...

Let’s dissect seven multiple sclerosis symptoms that Black people should recognize, and what they can do to address them.

FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter2024 to Discussthe Design of aCM-101 Accelerated Approval Phase 3Trial in Primary ...

A recent literature review presents a range of causes and treatments for chronic pruritus, including more novel options and a disease schematic for clinical decision support. The review has been ...

BRIDGEWATER, NJ / ACCESSWIRE / / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation ...

Mirum Pharmaceuticals ( (MIRM) ) has released its Q3 earnings. Here is a breakdown of the information Mirum Pharmaceuticals presented to its ...

Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has been assigned an average recommendation of “Hold” from the six ...